ASX: XETRA-DAX:  Level 1 ADR:CUV UR9 CLVLY EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five...
Enforcement Report - Week of April 27, 2022
Biopharmaceutical company CLINUVEL PHARMACEUTICALS LTD (ASX: CUV) completes its enrollment in the world-first study of stroke. At the time of writing this article, CUV shares were up 1.87% at AU$25.60 (AEDT: 11:50:46 AM).
MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL®, novel formulations of the melanocortin adrenocorticotropic hormone (ACTH). The Company has secured supply of ACTH with one of its strategic partners to meet existing global demand, and will be evaluating the potential of NEURACTHEL® for patients with neurological, endocrinological, and degenerative disorders, who lack alternative therapy.
CLINUVEL’s drug afamelanotide has been administered to a first patient diagnosed with an acute arterial ischaemic stroke (AIS) enrolled in a world’s first clinical trial (CUV801). Due to a clot formed in the higher region of the left middle cerebral artery (M2 or above), the patient suffered an acute stroke and was admitted to a specialist neurological hospital in Australia to receive treatment.
Australia based CLINUVEL Pharmaceuticals, has announced PRÉNUMBRA®, the Company’s second afamelanotide product in development.nnPRÉNUMBRA® is a liquid (non-solid) formulation of afamelanotide to be evaluated by CLINUVEL in clinical trials as a treatment for acute and systemic diseases.
At ICON we have built our reputation on enduring partnerships that are driven to advance medicine and make a difference in the world. Since our inception in 1990 we’ve strived to work as a ‘trusted partner’ to our clients, collaborating, innovating and finding new ways together to improve outcomes. It’s been the lifeblood of our business and the vision that has shaped our strategy more than any other.
The National Institute for Health and Care Excellence has rejected Clinuvel UK’s afamelanotide for treating erythropoietic protoporphyria (EPP) in preliminary guidelines deeming it far too expensive for NHS use.